These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16932335)

  • 1. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease.
    DeBoer MD; Marks DL
    Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):459-66. PubMed ID: 16932335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cachexia: lessons from melanocortin antagonism.
    Deboer MD; Marks DL
    Trends Endocrinol Metab; 2006 Jul; 17(5):199-204. PubMed ID: 16750633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanocortin interventions in cachexia: how soon from bench to bedside?
    DeBoer MD
    Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):457-62. PubMed ID: 17563464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MC4 receptor antagonists: a potential treatment for cachexia.
    Foster AC; Chen C; Markison S; Marks DL
    IDrugs; 2005 Apr; 8(4):314-9. PubMed ID: 15800806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticatabolic properties of melanocortin-4 receptor antagonists.
    Madison LD; Marks DL
    Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):196-200. PubMed ID: 16607116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanocortin-4 receptor in sheep: a potential site for therapeutic intervention in disease models.
    Sartin JL; Wagner CG; Marks DL; Daniel JA; McMahon CD; Obese FY; Partridge C
    Domest Anim Endocrinol; 2005 Aug; 29(2):446-55. PubMed ID: 15919173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on melanocortin interventions for cachexia: progress toward clinical application.
    DeBoer MD
    Nutrition; 2010 Feb; 26(2):146-51. PubMed ID: 20004082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of melanocortin antagonists in cachexia of chronic disease.
    Scarlett JM; Marks DL
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1233-9. PubMed ID: 16185165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of ghrelin as a treatment for cachexia syndromes.
    DeBoer MD
    Nutrition; 2008 Sep; 24(9):806-14. PubMed ID: 18725076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.
    Markison S; Foster AC; Chen C; Brookhart GB; Hesse A; Hoare SR; Fleck BA; Brown BT; Marks DL
    Endocrinology; 2005 Jun; 146(6):2766-73. PubMed ID: 15774557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
    Joppa MA; Gogas KR; Foster AC; Markison S
    Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the central melanocortin system in cachexia.
    Marks DL; Ling N; Cone RD
    Cancer Res; 2001 Feb; 61(4):1432-8. PubMed ID: 11245447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central mechanisms controlling appetite and food intake in a cancer setting: an update.
    Fletcher AL; Marks DL
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):306-11. PubMed ID: 18685380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.
    Nicholson JR; Kohler G; Schaerer F; Senn C; Weyermann P; Hofbauer KG
    J Pharmacol Exp Ther; 2006 May; 317(2):771-7. PubMed ID: 16436498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.
    von Haehling S; Stepney R; Anker SD
    Int J Cardiol; 2010 Oct; 144(3):347-9. PubMed ID: 20561693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia.
    Foster AC; Chen C
    Curr Top Med Chem; 2007; 7(11):1131-6. PubMed ID: 17584133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia.
    Mak RH; Cheung W; Cone RD; Marks DL
    Nat Clin Pract Nephrol; 2006 Sep; 2(9):527-34. PubMed ID: 16941045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cachexia: melanocortin and ghrelin interventions.
    Steinman J; DeBoer MD
    Vitam Horm; 2013; 92():197-242. PubMed ID: 23601426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activity.
    Tran JA; Tucci FC; Jiang W; Marinkovic D; Chen CW; Arellano M; Markison S; Fleck BA; Wen J; White NS; Pontillo J; Saunders J; Marks D; Hoare SR; Madan A; Foster AC; Chen C
    Bioorg Med Chem; 2007 Aug; 15(15):5166-76. PubMed ID: 17544282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists.
    Chen C; Tucci FC; Jiang W; Tran JA; Fleck BA; Hoare SR; Wen J; Chen T; Johns M; Markison S; Foster AC; Marinkovic D; Chen CW; Arellano M; Harman J; Saunders J; Bozigian H; Marks D
    Bioorg Med Chem; 2008 May; 16(10):5606-18. PubMed ID: 18417348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.